Hesham Shamshoum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hesham Shamshoum has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- David Charles Wright
University of British Columbia
3 shared publications - Greg L. McKie
Department of Human Health and Nutritional Sciences University of Guelph Guelph Ontario Canada
2 shared publications Alyssa J. Weber
Department of Human Health and Nutritional Sciences University of Guelph Guelph ON Canada
1 shared publicationBruce E. Kemp
Department of Medicine St. Vincent’s Institute University of Melbourne Melbourne Vic Australia
1 shared publicationChristopher G. R. Perry
School of Kinesiology and Health Science Muscle Health Research Centre York University Toronto ON Canada
1 shared publicationEmily A. Day
Centre for Metabolism, Obesity and Diabetes Research and Division of Endocrinology and Metabolism Department of Medicine McMaster University Hamilton ON Canada
1 shared publication
Latest Publications
- 17 May 2022
- Published by Wiley in The Journal of Physiology
- Vol. 600 (11) , 2713-2728
Fasting or the short‐term consumption of a ketogenic diet protects against antipsychotic‐induced hyperglycaemia in mice
Antipsychotic (AP) medications, such as olanzapine (OLZ), are used in the treatment of schizophrenia and a growing number of ‘off‐label’ conditions. A single dose of OLZ causes robust increases in blood glucose within minutes of treatment. The purpose of the current study was to investigate whether interventions that increase circulating ketone bodies (fasting, β‐hydroxybutyrate (βHB), ketone esters or a ketogenic diet (KD)) would be sufficient to protect against the acute metabolic side effects of OLZ. We demonstrate that fasting or the short‐term consumption of a KD protects against OLZ‐induced hyperglycaemia, independent of alterations in whole‐body insulin action, and in parallel with a blunted rise in serum glucagon. Interestingly, the effects of fasting and KDs were not recapitulated by acutely increasing circulating concentrations of ketone bodies through treatment with βHB or oral ketone esters, approaches which increase ketone bodies to physiological or supra‐physiological levels, respectively. Collectively, our findings demonstrate that fasting and the short‐term consumption of a KD can protect against acute AP‐induced perturbations in glucose homeostasis, whereas manipulations which acutely increase circulating ketone bodies do not elicit the same beneficial effects.Key points: Antipsychotic medications cause rapid and robust increases in blood glucose. Co‐treatment approaches to offset these harmful metabolic side effects have not been identified. We demonstrate that fasting or the consumption of a short‐term ketogenic diet, but not treatment with β‐hydroxybutyrate or oral ketone esters, protects against acute antipsychotic‐induced hyperglycaemia. The protective effects of fasting and ketogenic diets were paralleled by reductions in serum glucagon, but not improvements in whole‐body insulin action.
- 17 May 2022
- Published by Wiley in The Journal of Physiology
- Vol. 600 (11) , 2713-2728
Fasting or the short‐term consumption of a ketogenic diet protects against antipsychotic‐induced hyperglycaemia in mice
Antipsychotic (AP) medications, such as olanzapine (OLZ), are used in the treatment of schizophrenia and a growing number of ‘off‐label’ conditions. A single dose of OLZ causes robust increases in blood glucose within minutes of treatment. The purpose of the current study was to investigate whether interventions that increase circulating ketone bodies (fasting, β‐hydroxybutyrate (βHB), ketone esters or a ketogenic diet (KD)) would be sufficient to protect against the acute metabolic side effects of OLZ. We demonstrate that fasting or the short‐term consumption of a KD protects against OLZ‐induced hyperglycaemia, independent of alterations in whole‐body insulin action, and in parallel with a blunted rise in serum glucagon. Interestingly, the effects of fasting and KDs were not recapitulated by acutely increasing circulating concentrations of ketone bodies through treatment with βHB or oral ketone esters, approaches which increase ketone bodies to physiological or supra‐physiological levels, respectively. Collectively, our findings demonstrate that fasting and the short‐term consumption of a KD can protect against acute AP‐induced perturbations in glucose homeostasis, whereas manipulations which acutely increase circulating ketone bodies do not elicit the same beneficial effects.Key points: Antipsychotic medications cause rapid and robust increases in blood glucose. Co‐treatment approaches to offset these harmful metabolic side effects have not been identified. We demonstrate that fasting or the consumption of a short‐term ketogenic diet, but not treatment with β‐hydroxybutyrate or oral ketone esters, protects against acute antipsychotic‐induced hyperglycaemia. The protective effects of fasting and ketogenic diets were paralleled by reductions in serum glucagon, but not improvements in whole‐body insulin action.
- Open Access
- 14 February 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (3) , e22205
Topical application of the pharmacological cold mimetic menthol stimulates brown adipose tissue thermogenesis through a TRPM8, UCP1, and norepinephrine dependent mechanism in mice housed at thermoneutrality
Increasing whole‐body energy expenditure via the pharmacological activation of uncoupling protein 1 (UCP1)‐dependent brown adipose tissue (BAT) thermogenesis is a promising weight management strategy, yet most therapeutics studied in rodents to date either induce compensatory increases in energy intake, have thermogenic effects that are confounded by sub‐thermoneutral housing temperatures or are not well tolerated in humans. Here, we sought to determine whether the non‐invasive topical application of the pharmacological cold mimetic and transient receptor potential (TRP) cation channel subfamily M member 8 (TRPM8) agonist L‐menthol (MNTH), could be used to stimulate BAT thermogenesis and attenuate weight gain in mice housed at thermoneutrality. Using three different strains of mice and multiple complimentary approaches to quantify thermogenesis in vivo, coupled with ex vivo models to quantify direct thermogenic effects, we were able to convincingly demonstrate the following: (1) acute topical MNTH application induces BAT thermogenesis in a TRPM8‐ and UCP1‐dependent manner; (2) MNTH‐induced BAT thermogenesis is sufficient to attenuate weight gain over time without affecting energy intake in lean and obese mice; (3) the ability of topical MNTH application to stimulate BAT thermogenesis is mediated, in part, by a central mechanism involving the release of norepinephrine. These data collectively suggest that topical application of MNTH may be a promising weight management strategy.
- 14 February 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (3) , e22205
Open AccessTopical application of the pharmacological cold mimetic menthol stimulates brown adipose tissue thermogenesis through a TRPM8, UCP1, and norepinephrine dependent mechanism in mice housed at thermoneutrality
Increasing whole‐body energy expenditure via the pharmacological activation of uncoupling protein 1 (UCP1)‐dependent brown adipose tissue (BAT) thermogenesis is a promising weight management strategy, yet most therapeutics studied in rodents to date either induce compensatory increases in energy intake, have thermogenic effects that are confounded by sub‐thermoneutral housing temperatures or are not well tolerated in humans. Here, we sought to determine whether the non‐invasive topical application of the pharmacological cold mimetic and transient receptor potential (TRP) cation channel subfamily M member 8 (TRPM8) agonist L‐menthol (MNTH), could be used to stimulate BAT thermogenesis and attenuate weight gain in mice housed at thermoneutrality. Using three different strains of mice and multiple complimentary approaches to quantify thermogenesis in vivo, coupled with ex vivo models to quantify direct thermogenic effects, we were able to convincingly demonstrate the following: (1) acute topical MNTH application induces BAT thermogenesis in a TRPM8‐ and UCP1‐dependent manner; (2) MNTH‐induced BAT thermogenesis is sufficient to attenuate weight gain over time without affecting energy intake in lean and obese mice; (3) the ability of topical MNTH application to stimulate BAT thermogenesis is mediated, in part, by a central mechanism involving the release of norepinephrine. These data collectively suggest that topical application of MNTH may be a promising weight management strategy.
- Open Access
- 18 December 2020
- Published by Wiley in The FASEB Journal
- Vol. 35 (1) , e21218
AMPK mediates energetic stress‐induced liver GDF15
Growth differentiating factor‐15 (GDF15) is an emerging target for the treatment of obesity and metabolic disease partly due to its ability to suppress food intake. GDF15 expression and secretion are thought to be regulated by a cellular integrated stress response, which involves endoplasmic reticulum (ER) stress. AMPK is another cellular stress sensor, but the relationship between AMPK, ER stress, and GDF15 has not been assessed in vivo. Wildtype (WT), AMPK β1 deficient (AMPKβ1 −/− ), and CHOP −/− mice were treated with three distinct AMPK activators; AICAR, which is converted to ZMP mimicking the effects of AMP on the AMPKγ isoform, R419, which indirectly activates AMPK through inhibition of mitochondrial respiration, or A769662, a direct AMPK activator which binds the AMPKβ1 isoform ADaM site causing allosteric activation. Following treatments, liver Gdf15 , markers of ER‐stress, AMPK activity, adenine nucleotides, circulating GDF15, and food intake were assessed. AICAR and R419 caused ER and energetic stress, increased GDF15 expression and secretion, and suppressed food intake. Direct activation of AMPK β1 containing complexes by A769662 increased hepatic Gdf15 expression, circulating GDF15, and suppressed food intake, independent of ER stress. The effects of AICAR, R419, and A769662 on GDF15 were attenuated in AMPKβ1 −/− mice. AICAR and A769662 increased GDF15 to a similar extent in WT and CHOP −/− mice. Herein, we provide evidence that AMPK plays a role in mediating the induction of GDF15 under conditions of energetic stress in mouse liver in vivo.
- 18 December 2020
- Published by Wiley in The FASEB Journal
- Vol. 35 (1) , e21218
Open AccessAMPK mediates energetic stress‐induced liver GDF15
Growth differentiating factor‐15 (GDF15) is an emerging target for the treatment of obesity and metabolic disease partly due to its ability to suppress food intake. GDF15 expression and secretion are thought to be regulated by a cellular integrated stress response, which involves endoplasmic reticulum (ER) stress. AMPK is another cellular stress sensor, but the relationship between AMPK, ER stress, and GDF15 has not been assessed in vivo. Wildtype (WT), AMPK β1 deficient (AMPKβ1 −/− ), and CHOP −/− mice were treated with three distinct AMPK activators; AICAR, which is converted to ZMP mimicking the effects of AMP on the AMPKγ isoform, R419, which indirectly activates AMPK through inhibition of mitochondrial respiration, or A769662, a direct AMPK activator which binds the AMPKβ1 isoform ADaM site causing allosteric activation. Following treatments, liver Gdf15 , markers of ER‐stress, AMPK activity, adenine nucleotides, circulating GDF15, and food intake were assessed. AICAR and R419 caused ER and energetic stress, increased GDF15 expression and secretion, and suppressed food intake. Direct activation of AMPK β1 containing complexes by A769662 increased hepatic Gdf15 expression, circulating GDF15, and suppressed food intake, independent of ER stress. The effects of AICAR, R419, and A769662 on GDF15 were attenuated in AMPKβ1 −/− mice. AICAR and A769662 increased GDF15 to a similar extent in WT and CHOP −/− mice. Herein, we provide evidence that AMPK plays a role in mediating the induction of GDF15 under conditions of energetic stress in mouse liver in vivo.